Amendments to the Claims

Please amend claims 1, 8-10, 14-16, 18, 20, 22, 24 and 27-29 as follows. Please cancel claims 17 and 21 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of therapeutically or prophylactically treating graft versus host disease (GVHD), ~~including the steps of~~ **said method comprising:**

(i) administering a pharmaceutically-effective amount of chaperonin 10 (cpn10) or a derivative of cpn10 to a donor animal or cell, organ or tissue obtained therefrom; and

(ii) administering to a recipient animal a pharmaceutically-effective amount of cpn10 or a derivative of cpn10, to thereby delay, ameliorate, suppress or otherwise reduce one or more symptoms of GVHD following transplantation of the one or more cells, tissues or organs **from the donor animal** to the recipient animal.

2. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of chaperonin 10 or a derivative of cpn10 is administered to a recipient animal both before and after step (ii).

3. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the donor and recipient animals for no more than 7 days prior to step (ii).

4. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the donor and recipient animals for 2 to 5 days prior to step (ii).

5. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the recipient animal for no more than 90 days after step (ii).

6. (Original) The method of claim 5 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the recipient animal for no more than 60 days after step (ii).

7. (Original) The method of claim 6 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the recipient animal for 10 to 30 days after step (ii).

8. (Currently amended) The method of ~~any one of claims 1 to 7~~ **claim 1** wherein said cpn10 protein has an amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).

9. (Currently amended) The method of claim 1 wherein the pharmaceutically-effective amount of cpn10 or derivative of cpn10 administered to an animal is within the range 0.1-100 mg**/kg body** ~~per kg/body~~ weight.

10. (Currently amended) The method of claim 9 wherein the pharmaceutically-effective amount of cpn10 or derivative of cpn10 administered to an animal is within the range 0.1-10 mg**/kg body** ~~per kg/body~~ weight.

11. (Original) The method of claim 1 wherein the cell, tissue or organ is, or is derived from, bone marrow.

12. (Original) The method of claim 1 wherein said animal is a mammal.

13. (Original) The method of claim 12 wherein said mammal is a human.

14. (Currently amended) The method of claim 1 further ~~including the step of~~ **comprising** administering to said donor animal and/or said recipient animal at least one other immunosuppressive agent selected from the group consisting of cyclosporin, tacrolimus, sirolimus, mycophenolate, mofetil and methotrexate.

15. (Currently amended) The method of claim 1 further ~~including the step of~~ **comprising** administering to said donor animal and/or recipient animal a steroid.

16. (Currently amended) A method of inhibiting, suppressing or otherwise reducing TNFα production in an animal **or by one or more cells, tissues or organs obtained from said animal, said method comprising** ~~**including the step of**~~ administering to said animal **or said cells, tissues or organs obtained therefrom** a pharmaceutically-effective amount of cpn10 or derivative of cpn10 to thereby inhibit, suppress or otherwise reduce production of TNFα in said animal **or said cells, tissues or organs obtained therefrom**.

17. (Cancelled)

18. (Currently amended) The method of claim 16 ~~**or claim 17**~~ wherein said animal is a mammal.

19. (Original) The method of claim 18 wherein said mammal is a human.

20. (Currently amended) A method of inducing, augmenting or otherwise increasing IL-10 production in an animal **or by one or more cells, tissues or organs obtained from said animal, said method comprising** ~~**including the step of**~~ administering to said animal **or said cells, tissues or organs obtained therefrom** a pharmaceutically-effective amount of cpn10 or derivative of cpn10 to thereby induce, augment or otherwise increase production of ID-10 in said animal **or said cells, tissues or organs obtained therefrom**.

21. (Cancelled)

22. (Currently amended) The method of claim 20 ~~**or claim 21**~~ wherein said animal is a mammal.

23. (Original) The method of claim 22 wherein said mammal is a human.

24. (Currently amended) A pharmaceutical composition ~~**for use according to the method of claims 1, 16 or 17**~~ comprising a pharmaceutically-effective amount of cpn10 or a derivative of cpn10, and a pharmaceutically-acceptable carrier, excipient or diluent.

25. (Original) The pharmaceutical composition of claim 24 further comprising at least one other immuunosuppressive agent.

26. (Original) The pharmaceutical composition of claim 25 wherein the other immunosuppressive agent is an immunosuppressive drug or a specific antibody directed against B or T lymphocytes or surface receptors that mediate their activation.

27. (Currently amended) The pharmaceutical composition of claim 25 wherein the other immunosuppressive agent is ~~any one~~ **selected from the group consisting** of cyclosporin, tacrolimus, sirolimus, mycophenolate mofetil and methotrexate.

28. (Currently amended) The pharmaceutical composition of ~~any one of claims 24 to 27~~ **claim 24** further comprising a steroid.

29. (Currently amended) The pharmaceutical composition of ~~any preceding~~ claim **24** wherein cpn10 has an amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).